228 related articles for article (PubMed ID: 35684158)
1. 11β-HSD1 Inhibitor Alleviates Non-Alcoholic Fatty Liver Disease by Activating the AMPK/SIRT1 Signaling Pathway.
Chen Y; Li J; Zhang M; Yang W; Qin W; Zheng Q; Chu Y; Wu Y; Wu D; Yuan X
Nutrients; 2022 Jun; 14(11):. PubMed ID: 35684158
[TBL] [Abstract][Full Text] [Related]
2. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice.
Yuan X; Li H; Bai H; Zhao X; Zhang C; Liu H; Zhang Y; Zhao B; Wu Y; Liu J; Xiang Q; Feng B; Chu Y; Huang Y
Eur J Pharmacol; 2016 Oct; 788():140-151. PubMed ID: 27242185
[TBL] [Abstract][Full Text] [Related]
3. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
4. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
5. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.
Larner DP; Morgan SA; Gathercole LL; Doig CL; Guest P; Weston C; Hazeldine J; Tomlinson JW; Stewart PM; Lavery GG
Endocrinology; 2016 Sep; 157(9):3493-504. PubMed ID: 27384305
[TBL] [Abstract][Full Text] [Related]
6. Patchouli alcohol ameliorates skeletal muscle insulin resistance and NAFLD via AMPK/SIRT1-mediated suppression of inflammation.
Pyun DH; Kim TJ; Park SY; Lee HJ; Abd El-Aty AM; Jeong JH; Jung TW
Mol Cell Endocrinol; 2021 Dec; 538():111464. PubMed ID: 34601002
[TBL] [Abstract][Full Text] [Related]
7. Protopanaxadiol ameliorates NAFLD by regulating hepatocyte lipid metabolism through AMPK/SIRT1 signaling pathway.
Li Y; Liu Y; Chen Z; Tang K; Yang L; Jiang Y; Wang J; Huang P; Wang J; Zheng P; Song H
Biomed Pharmacother; 2023 Apr; 160():114319. PubMed ID: 36724639
[TBL] [Abstract][Full Text] [Related]
8. Salvia-Nelumbinis naturalis improves lipid metabolism of NAFLD by regulating the SIRT1/AMPK signaling pathway.
Liu Y; Li Y; Wang J; Yang L; Yu X; Huang P; Song H; Zheng P
BMC Complement Med Ther; 2022 Aug; 22(1):213. PubMed ID: 35945571
[TBL] [Abstract][Full Text] [Related]
9. The GR-gp78 Pathway is involved in Hepatic Lipid Accumulation Induced by Overexpression of 11β-HSD1.
Hu M; Han T; Pan Q; Ni D; Gao F; Wang L; Ren H; Zhang X; Jiao H; Wang Y; Dai D; Man Y; Tang W; Sun Y; Li W; Li J; Li G
Int J Biol Sci; 2022; 18(8):3107-3121. PubMed ID: 35637957
[TBL] [Abstract][Full Text] [Related]
10. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
Li Q; Tan JX; He Y; Bai F; Li SW; Hou YW; Ji LS; Gao YT; Zhang X; Zhou ZH; Yu Z; Fang M; Gao YQ; Li M
Int J Biol Sci; 2022; 18(4):1594-1611. PubMed ID: 35280674
[No Abstract] [Full Text] [Related]
11. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
Zhang J; Du H; Shen M; Zhao Z; Ye X
J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
[TBL] [Abstract][Full Text] [Related]
12. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
13. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
[TBL] [Abstract][Full Text] [Related]
14. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
Yao H; Tao X; Xu L; Qi Y; Yin L; Han X; Xu Y; Zheng L; Peng J
Pharmacol Res; 2018 May; 131():51-60. PubMed ID: 29574225
[TBL] [Abstract][Full Text] [Related]
15. A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease.
Ahmed A; Rabbitt E; Brady T; Brown C; Guest P; Bujalska IJ; Doig C; Newsome PN; Hubscher S; Elias E; Adams DH; Tomlinson JW; Stewart PM
PLoS One; 2012; 7(2):e29531. PubMed ID: 22363403
[TBL] [Abstract][Full Text] [Related]
16. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
17. Curcumin as a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase 1: improving lipid profiles in high-fat-diet-treated rats.
Hu GX; Lin H; Lian QQ; Zhou SH; Guo J; Zhou HY; Chu Y; Ge RS
PLoS One; 2013; 8(3):e49976. PubMed ID: 23533564
[TBL] [Abstract][Full Text] [Related]
18. Berbamine induced activation of the SIRT1/LKB1/AMPK signaling axis attenuates the development of hepatic steatosis in high-fat diet-induced NAFLD rats.
Sharma A; Anand SK; Singh N; Dwarkanath A; Dwivedi UN; Kakkar P
Food Funct; 2021 Jan; 12(2):892-909. PubMed ID: 33411880
[TBL] [Abstract][Full Text] [Related]
19. Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Attenuates High-Fat Diet-Induced Hepatic Steatosis in Mice.
Li H; Sheng J; Wang J; Gao H; Yu J; Ding G; Ding N; He W; Zha J
Drug Des Devel Ther; 2021; 15():2309-2324. PubMed ID: 34103895
[TBL] [Abstract][Full Text] [Related]
20. Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway.
Li N; Yin L; Shang J; Liang M; Liu Z; Yang H; Qiang G; Du G; Yang X
Biomed Pharmacother; 2023 Sep; 165():115113. PubMed ID: 37418974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
